Introduction
============

Colorectal cancer (CRC) is one of the most common malignancies and a leading cause in the last decade of cancer-related death worldwide;[@b1-cmar-10-2151],[@b2-cmar-10-2151] it is also the fifth most common cancer and the fifth leading cause of death in China.[@b3-cmar-10-2151] Although substantial progress had been achieved in decades, \~60% of CRC individuals were diagnosed with node or distant metastasis and the 5 years' survival rate was merely 65% from 2006 to 2012.[@b4-cmar-10-2151] Thus, novel, effective, stable, and economical biomarkers may help to improve diagnostic and predictive efficacy of the disease.

It was reported that an estimated 15% of the cancer-related death was attributed to chronic inflammation,[@b5-cmar-10-2151] and accumulating evidence indicated that inflammation was one of the most crucial causes facilitating onset and metastasis of CRC.[@b6-cmar-10-2151] Recent studies have found vital roles of inflammation-induced genetic alternation, immune cells, cytokines, and other mediators in each step of colonic tumorigenesis and progression.[@b7-cmar-10-2151]--[@b10-cmar-10-2151] Moreover, the continuous use of low-dose nonsteroidal anti-inflammatory drugs was associated with a decreased risk of CRC.[@b11-cmar-10-2151],[@b12-cmar-10-2151]

Systematic chronic inflammation could contribute to both abnormal peripheral immune cell count and aberrant concentrations of circulating albumin (Alb) and pre-albumin (pre-Alb) as well as fibrinogen (Fib). Our preview study indicated that preoperative neutrophil-to-lymphocyte ratio was an independent prognostic factor for poor recurrence-free survival and overall survival (OS) in CRC.[@b13-cmar-10-2151] Several studies showed that elevated pretreatment plasma Fib was associated with short progression-free survival in various malignancies, including CRC.[@b14-cmar-10-2151],[@b15-cmar-10-2151] Moreover, Alb and pre-Alb were observed to be significantly lower in cancer individuals in comparison with the healthy controls.[@b16-cmar-10-2151],[@b17-cmar-10-2151] Hence, we hypothesized that the two new biomarkers, Alb-to-Fib ratio (AFR) and Fib-to-pre-Alb ratio (FPR), might reflect the severity of systemic inflammation and predict the survival of CRC individuals.

In this study, we measured the preoperative circulating levels of Fib, Alb, pre-Alb, carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA199) and performed 3 years' follow-up to evaluate potential prognostic roles of them in 702 stage I--III surgically resected CRC individuals. Furthermore, we established and compared the prognostic efficacy of CEA-CA199-FPR (CCF), CEA-CA199 (CCI), and CEA-FPR (CFI) scores. Finally, we evaluated the roles of FPR, CEA, CA199, and CCF in predicting clinical efficacy of adjuvant chemotherapy among stage II--III CRC patients.

Materials and methods
=====================

Population
----------

In our study, 702 stage I--III CRC individuals were included. All of them were first diagnosed, and pathologically confirmed according to the seventh edition of TNM/The Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) classification, and were without hematologic, hepatic, autoimmune diseases, recent infection, or other malignancies, and were from the Second Affiliated Hospital of Nanchang University and Nanjing First Hospital between January 2008 and December 2013. All the enrolled patients had only radical resection performed, without preoperative neoadjuvant radiochemotherapy, and the clinical characteristics and follow-up data were obtained from each patient. To compare the difference of FPR in recurrent/distant metastatic CRC patients and in the progression-free patients, the controls were randomly selected to match the recurrent or distant metastatic cases with gender and age in the ratio of 1:1, and all of them were from the progression-free patients in the follow-up period. Written informed consents were signed by each eligible patient, and the study was approved by the institutional ethic commissions of the Second Affiliated Hospital of Nanchang University and Nanjing First Hospital.

Data collection and laboratory detection
----------------------------------------

We collected clinical baseline characteristics of all the patients from medical records. All preoperative sodium citrate anticoagulant peripheral blood and serum samples were collected at 7:30--9:30 am in the period before the intervention. Clauss method was selected to detect circulating Fib using SYSMEX CA-7000 machine (Sysmex, Tokyo, Japan), and inter- and intrabatch coefficients of variation (CVs) of the kit were \<4.41% and 3.66%, respectively. Bromocresol green and immune turbidimetric methods were used to measure serum Alb and pre-Alb using OLYMPUS AU5400 machine (Beckman Coulter, Tokyo, Japan), and the inter- and intra-batch CVs of the kits were \<3.17% and 1.83%, and 3.09% and 2.76%, respectively. Electrochemiluminescence immunoassay was used to detect CEA and CA199 by a machine from Siemens ADVIA Centaur CP (Siemens, Erlangen, Germany), and the respective inter- and intrabatch CVs of the kits were \<3.32% and 3.25%, and 3.48% and 3.26%.

Follow-up
---------

We performed 3 years of follow-up regularly, by means of telephone, email, and medical record, every 3 months for the first 2 years and every 6 months in the third year. The deadline of the follow-up was December 2016. OS was the end point of the study, and it was calculated from the time of surgical resection to death or the deadline.

Construction of novel prognostic score
--------------------------------------

To further investigate the prognostic values of FPR, CEA, and CA199, we established and compared the CCI, CFI, and CCF scores. The CCI score was composed of CEA and CA199, and the patient with both CEA \>5 ng/mL and CA199 \>37 U/mL was given a score of 2, and patients with only one or neither of these abnormalities were allocated a score of 1 or 0, respectively. Similarly, the patient with both elevated CEA (\>5 ng/mL) and FPR (\>18.3) was allocated a CFI score of 2, and patients with only one or neither of these elevated levels were allocated a score of 1 or 0, respectively. Additionally, CCF score consisted of preoperative FPR, CEA, and CA199, and patients with either none, one, two, or three elevated levels of them (CEA\>5ng/ml, CA199\>37U/ml, FPR\>18.3) were considered as 0, 1, 2, and 3 score, respectively.

Statistics
----------

The optimal cutoff points of FPR, AFR, Fib, and Alb were determined by X-tile software version 3.6.1 (Yale University, New Haven, CT, USA), and were based on 3 years' OS. Chi-square test or Fisher's exact test were used to compare the categorical variable in the groups, and Mann--Whitney *U* or Student's *t*-test were selected to examine the difference in continuous variables. The sample power was evaluated using PASS version 11.0.10 program (NCSS, California, USA). The difference in survival rate was calculated using Kaplan--Meier curve with log-rank test, and the independent prognostic predictor was identified by Cox proportional hazards model. The predicted efficacy of the prognostic predictors was assessed by time-dependent receiver operating characteristics (ROC) analysis. We established a 3 years' OS nomogram using R 3.3.2 software (Institute for Statistics and Mathematics, Vienna, Austria), and the predictive accuracy was evaluated by Harrell's concordance index (c-index). A *p*-value \<0.05 was recognized as statistical significance, and all the statistical analyses were conducted using IBM SPSS 20.0 software (IBM Corporation, Armonk, NY, USA).

Results
=======

Baseline characteristics of patients
------------------------------------

The baseline characteristics of CRC patients in the present study are summarized in [Table S1](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D167398.pdf). A total of 702 patients were recruited in our study, and the powers of the sample size were 0.99 for FPR, 0.89 for AFR, 0.93 for Fib, 0.98 for pre-Alb, and 0.85 for Alb. The majority of included patients were stage II (44%) and stage III (43%) cases, and proportions of the cases with T1--T2 and T3--T4 depth were 15.2% and 84.8%, respectively. Lymph-node metastasis was observed in 302 patients, and 89.3% of the patients were G1--G2 grade cases. Moreover, 66.1% of the eligible patients received adjuvant chemotherapy. Three hundred twenty-three (62.0%), 152 (29.2%), and 46 (8.8%) patients were allocated CCI score 0, 1, and 2, respectively. Two hundred twenty-eight (43.6%), 209 (40.0%), and 86 (16.4%) patients harbored CFI 0, 1, and 2 score, respectively. The respective numbers of patients with CCF score 0, 1, 2, and 3 were 210 (40.3%), 190 (36.5%), 97 (18.6%), and 24 (4.6%). Up to follow-up deadline, 123 patients had died and 128 patients had confirmed recurrence or distant metastasis in our study.

Correlation of FPR, AFR, Fib, Alb, and pre-Alb with clinical characteristics
----------------------------------------------------------------------------

Using X-tile software, we found that the optimal cutoff points based on OS were 3.8 g/L for Fib, 33.3 g/L for Alb, 187.4 mg/L for pre-Alb, 18.3 for FPR, and 9.2 for AFR ([Figure 1](#f1-cmar-10-2151){ref-type="fig"} and [Figure S1](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D167398.pdf)). The relationships between the biomarkers and clinical characteristics are described in [Table 1](#t1-cmar-10-2151){ref-type="table"}. All of the biomarkers were closely associated with age \>60 years, large tumor size, and poor OS. FPR, AFR, and Fib were significantly associated with tumor size, depth of invasion, and node metastasis. Furthermore, circulating FPR in patients with stage III--IV, T3--T4 depth, N1--N2 metastasis, and tumor size \>5cm was higher than in those with stage I--II, T1--T2 depth, N0 metastasis, and tumor size ≤5cm, respectively ([Figure 2](#f2-cmar-10-2151){ref-type="fig"}, [Table S2](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D167398.pdf)). Besides, we compared the difference in circulating FPR in 128 randomly selected nonrecurrent/metastatic patients and 128 recurrent/metastatic patients. Intriguingly, FPR in recurrent patients was significantly higher than that of nonrecurrent/metastatic patients (*p*\<0.05).

Prognostic roles of FPR, AFR, Fib, Alb, and pre-Alb in CRC
----------------------------------------------------------

In the present study, the Kaplan--Meier curve with log-rank test and Cox proportion regression model were selected to investigate the prognostic roles of the baseline characteristics and FPR, AFR, Fib, Alb, and pre-Alb in CRC. As shown in [Figure 3](#f3-cmar-10-2151){ref-type="fig"}, FPR (\>18.3), AFR (≤9.2), Fib (\>3.8 g/L), Alb (≤33.3 g/L), and pre-Alb (≤187.4 mg/L) were negatively associated with 3 years' OS in the Kaplan--Meier curve. G3--G4 differentiation (crude hazard ratio \[HR\]=1.867, 95% CI=1.145--3.046; adjusted HR=1.718, 95% CI=1.052--2.805), stage III (crude HR=3.834, 95% CI=1.567--9.381; adjusted HR=3.368, 95% CI=1.370--8.280), T3--T4 depth (crude HR=3.792, 95% CI=1.669--8.614; adjusted HR=2.792, 95% CI=1.208--6.452), lymph-node metastasis (crude HR=1.934, 95% CI=1.354--2.762; adjusted HR=1.888, 95% CI=1.322--2.698), large tumor size (\>5 cm) (crude HR=1.979, 95% CI=1.389--2.819; adjusted HR=1.905, 95% CI=1.336--2.715), high CEA (\>5 ng/mL; crude HR=2.961, 95% CI=2.019--4.342; adjusted HR=2.719, 95% CI=1.850--3.996), and CA199 (\>37 U/mL; crude HR=2.916, 95% CI=1.934--4.398; adjusted HR=2.605, 95% CI=1.683--4.033) were significantly correlated with poor OS ([Table 2](#t2-cmar-10-2151){ref-type="table"}).

Circulating elevated FPR (crude HR=2.398, 95% CI=1.567--3.669; adjusted HR=1.940, 95% CI=1.236--3.046) was significantly associated with an increased death risk from CRC, whereas high Alb (crude HR=0.504, 95% CI=0.315--0.806; adjusted HR=0.564, 95% CI=0.349--0.912) and pre-Alb (crude HR=0.444, 95% CI=0.287--0.687; adjusted HR=0.520, 95% CI=0.329--0.823) were significantly associated with decreased death risk from the disease. However, no correlations were observed between AFR, Fib, and OS ([Table 2](#t2-cmar-10-2151){ref-type="table"}).

Analysis of time-dependent ROC
------------------------------

Time-dependent ROC was used to compare the prognostic efficacy of each biomarker in our study. The areas under the ROC (AUCs) of FPR, Alb, and pre-Alb were larger than for the other biomarkers in the first few months ([Figure 3I](#f3-cmar-10-2151){ref-type="fig"}). Comparatively, AUC of FPR stayed at the higher level compared to Alb and pre-Alb, in the following months. In addition, CEA had the largest AUC in the last 24 months.

Prognostic values of CCI, CFI, and CCF scores
---------------------------------------------

To further investigate the prognostic values of FPR, CEA, and CA199, we established and assessed the prognostic roles of CCI, CFI, and CCF scores. The higher CCI (crude HR=2.495 and adjusted HR=2.289 for score 1; crude HR=5.926 and adjusted HR=5.612 for score 2), CFI (crude HR=3.021 and adjusted HR=2.748 for score 1; crude HR=6.957 and adjusted HR=5.904 for score 2), and CCF (crude HR=2.770 and adjusted HR=2.578 for score 1; crude HR=5.902 and adjusted HR=4.753 for score 2; crude HR=12.082 and adjusted HR=11.518 for score 3) were significantly associated with reduced survival of the CRC patients ([Figure 4](#f4-cmar-10-2151){ref-type="fig"} and [Table S3](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D167398.pdf)).

Predictive roles of FPR, CEA, CA199, and CCF in chemotherapy
------------------------------------------------------------

To investigate the predictive roles of FPR, CEA, CA199, and CCF in adjuvant chemotherapy, we compared the survival difference of surgical stage II--III CRC patients with or without treatment of chemotherapy in each high or low FPR, CEA, CA199, and CCF subgroup. We found that OS of the patients with adjuvant chemotherapy was significantly longer than in those without it, only in CCF≥1 score (*p*\<0.05, adjusted HR=0.494, 95% CI=0.303--0.806) and high FPR (*p*\<0.05, adjusted HR=0.420, 95% CI=0.241--0.731) subgroups. However, no survival difference was observed in the low FPR and CCF score subgroups, or in all subgroups stratified by CEA and CA199 ([Figure 5](#f5-cmar-10-2151){ref-type="fig"} and [Figure S2](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D167398.pdf)).

Assessment of the constructed nomograms
---------------------------------------

The pivotal clinical pathologic characteristics, FPR, and CCF scores were selected to construct prognostic nomograms to predict 3 years' OS of CRC and the predicted accuracy was evaluated by Harrell's c-index. The nomograms are listed in [Figure 6](#f6-cmar-10-2151){ref-type="fig"} and [Figure S3](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D167398.pdf); c-indexes of the nomograms with or without CCF score were 0.728 (0.677--0.777) and 0.626 (0.568--0.684), and c-indexes of those with or without FPR were 0.722 (0.667--0.777) and 0.706 (0.648--0.764), respectively. Moreover, the significant difference between c-indexs of the nomogram with or without CCF score was observed between them (*p*\<0.01).

Discussion
==========

Systemic inflammation is one of the important hallmarks of CRC.[@b7-cmar-10-2151] CRC cells, cancer stem cells, chronic inflammatory mediators, and inflammation-related cells, such as cancer-associated fibroblasts and endothelial cells, as well as tumor-associated macrophages form a favorable microenvironment to promote carcinogenesis of colorectal epithelial cells and to create a pre-metastatic niche in secondary organs or tissue sites for subsequent metastasis.[@b18-cmar-10-2151]--[@b20-cmar-10-2151] Circulating Fib, Alb, and pre-Alb were the main inflammatory biomarkers, and hyperfibrinogenemia and hypoalbuminemia were commonly observed in CRC patients.[@b21-cmar-10-2151],[@b22-cmar-10-2151] However, the prognostic and predictive roles of AFR and FPR in surgically resected CRC remained unknown.

We conducted this prospective study to investigate the association of preoperative AFR, FPR, Fib, Alb, pre-Alb, CEA, and CA199 with 3 years' OS in 702 I--III surgically resected CRC individuals. Our results showed that low AFR, Alb, pre-Alb, and elevated Fib level were only associated with T3--T4 invasion and tumor size. However, elevated FPR was significantly associated with TNM stage, invasion depth, node metastasis, and tumor size. These results indicated that FPR was superior to these biomarkers to in evaluating CRC progression and the tumor burden. Furthermore, low Alb and pre-Alb, and high FPR were significantly associated with poor survival of CRC, and the predicted efficacy of FPR was significantly higher than the others, demonstrating that it was an effective and independent prognostic factor to predict the prognosis of CRC.

In addition to the single inflammatory biomarker, the emerging novel prognostic scores have been proposed to evaluate the progression and survival of CRC. Glasgow prognostic score (GPS) and modified GPS showed good performance in predicting clinical outcome of CRC.[@b23-cmar-10-2151],[@b24-cmar-10-2151] Depending on FPR, CEA, and CA199, three novel CFI, CCI, and CCF scores were first established in our study, and they were obviously associated with the survival of CRC; however, the measured HRs of CCI and CFI score were less than CCF score, suggesting that the two scores were inferior to CCF to predict survival of CRC. Moreover, no significant survival difference of stage II--III CRC patients with or without adjuvant chemotherapy was observed in any subgroup stratified by CEA and CA199, whereas the cases that harbored high FPR and CCF score could benefit from adjuvant chemotherapy, illustrating that FPR and CCF score were useful biomarkers to precisely distinguish eligible patients who could benefit from the treatment. The c-index of the nomogram containing FPR or CCF was significantly higher than the nomogram without them, suggesting that FPR and CCF could improve predicted accuracy of the prognostic nomogram.

Notably, Fib is not only an important factor in the blood coagulation cascade but also a main acute phase reaction protein in chronic inflammation. Tumor cells could interact with all parts of the hemostatic system to stimulate prothrombotic properties and to trigger the production of Fib by liver and by itself,[@b25-cmar-10-2151] contributing to the high level of Fib. Meanwhile, Fib was considered as a mediator of cancer cell proliferation;[@b26-cmar-10-2151] it sustained the adhesion and survival of cancer cell emboli in the vasculature of target organs to promote metastasis,[@b27-cmar-10-2151] and it could protect cancer cells escaping elimination by natural killer cells by means of formation of a shielding cover around them.[@b28-cmar-10-2151] Moreover, the common inflammatory cytokine, interleukin-6, was reported to suppress the synthesis of Alb and pre-Alb, leading to hypoproteinemia in CRC patients.[@b29-cmar-10-2151] Consequently, poor nutritional status and impaired immunologic surveillance of the patient directly affected clinical outcome of the disease.[@b29-cmar-10-2151],[@b30-cmar-10-2151] Thus, these factors might have accounted for the findings in the present study.

Our study is the first to evaluate the prognostic roles of AFR, FPR, and CCF score in survival of CRC patients. The established nomogram containing CCF was an easy-to-use system for accurately estimating 3 years' survival of CRC patients after surgery. However, some limitations in the current study should be addressed. First, the diverse postoperative chemotherapy regimens might lead to the heterogeneous outcome of the patients. Secondly, only 3 years' OS was included in our study, and we did not obtain the complete recurrence data and 5 years' of OS, so our study can not comprehensively reflect survival of the patients. Thirdly, no validated cohort was included to verify the findings in our study.

Conclusion
==========

In summary, our data have revealed that FPR and CCF score are reliable, economical, and practical biomarkers to precisely distinguish eligible patients for treatment with adjuvant chemotherapy and to predict the prognosis of CRC. Further, multicenter and large sample size design studies are warranted to validate our results.
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![The optimal cutoff value of preoperative circulating FPR in 702 CRC patients using X-tile software.\
**Notes:** The data are represented graphically in a right-triangular grid where the point represents the data from a given set of divisions (**A**). The plots showed the χ^2^ log-rank values produced, dividing them into three groups by the cutoff points 18.3 and 30.2. The optimal cutoff point, 18.3, was determined by locating the brightest pixel on the X-tile plot. The distribution of number of patients is shown on the histogram (**B**) and the corresponding populations are displayed on the Kaplan--Meier curve (**C**). Larger low population= larger population with low FPR level; larger high population= larger population with high FPR level.\
**Abbreviations:** CRC, colorectal cancer; FPR, fibrinogen-to-pre-albumin ratio.](cmar-10-2151Fig1){#f1-cmar-10-2151}

![The correlation of FPR with clinical characteristics and comparison of FPR in nonrelapse and recurrent CRC patients.\
**Notes:** (**A**) FPR with depth of invasion; (**B**) FPR with lymph node; (**C**) FPR with tumor grade; (**D**) FPR with tumor size; (**E**) FPR with tumor stage; (**F**) comparison of FPR in nonrelapse and recurrent CRC patients. \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001.\
**Abbreviations:** CRC, colorectal cancer; FPR, fibrinogen-to-pre-albumin ratio; NS, no significance.](cmar-10-2151Fig2){#f2-cmar-10-2151}

![Kaplan--Meier curves of FPR, AFR, Fib, Alb, and pre-Alb for 3 years' OS in 702 CRC patients.\
**Notes:** (**A**) Alb; (**B**) pre-Alb; (**C**) Fib; (**D**) AFR; (**E**) FPR; (**F**) CCI; (**G**) CFI; (**H**) CCF. Time-dependent receiver operating characteristic analysis of preoperative circulating FPR, Alb, pre-Alb, CA199, and CEA for clinical outcome of 702 CRC patients (**I**).\
**Abbreviations:** AFR, albumin-to-fibrinogen ratio; Alb, albumin; pre-Alb, pre-albumin; CA199, carbohydrate antigen 19-9; CCF, CEA-CA199-FPR; CCI, CEA-CA199; CEA, carcinoembryonic antigen; CFI, CEA-FPR; CRC, colorectal cancer; Fib, fibrinogen; FPR, fibrinogen-to-pre-albumin ratio; HR, hazard ratio; OS, overall survival.](cmar-10-2151Fig3){#f3-cmar-10-2151}

![The HRs of CCI, CFI, and CCF scores in CRC patients.\
**Notes: (A)** The crude and adjusted HRs of CCI and CFI score; (**B**) The crude and adjusted HRs of CCF score.\
**Abbreviations:** CCF, CEA-CA199-FPR; CCI, CEA-CA199; CA199, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CFI, CEA-FPR; CRC, colorectal cancer; HR, hazard ratio; FPR, fibrinogen-to-pre-albumin ratio.](cmar-10-2151Fig4){#f4-cmar-10-2151}

![Kaplan--Meier curves of stage II--III CRC patients with or without treatment of chemotherapy in each subgroup stratified by FPR, CFI, and CCF.\
**Notes: (A)** FPR≤18.3; (**B)** FPR\>18.3; **(C)** CFI=0; **(D)** CFI≥1; **(E)** CCF=0; **(F)** CCF≥1.\
**Abbreviations:** CCF, CEA-CA199-FPR; CFI, CEA-FPR; CRC, colorectal cancer; FPR, fibrinogen-to-pre-albumin ratio; OS, overall survival.](cmar-10-2151Fig5){#f5-cmar-10-2151}

![Prognostic nomograms with or without CCF score for predicting 3-year OS in CRC patients.\
**Notes: (A)** Nomogram without CCF; **(B)** Nomogram including CCF.\
**Abbreviations:** CCF, CEA-CA199-FPR; CRC, colorectal cancer; FPR, fibrinogen-to-pre-albumin ratio; OS, overall survival.](cmar-10-2151Fig6){#f6-cmar-10-2151}

###### 

Correlations of preoperative circulating Fib, Alb, pre-Alb, AFR, and FPR with clinicopathologic characteristics in 702 CRC patients

  Characteristics              Patients grouped by FPR level (n=555)   *p*-value[\*](#tfn1-cmar-10-2151){ref-type="table-fn"}   Patients grouped by AFR level (n=680)   *p*-value[\*](#tfn1-cmar-10-2151){ref-type="table-fn"}   Patients grouped by Fib level (n=682)   *p*-value[\*](#tfn1-cmar-10-2151){ref-type="table-fn"}   Patients grouped by Alb level (n=700)   *p*-value[\*](#tfn1-cmar-10-2151){ref-type="table-fn"}   Patients grouped by pre-Alb level (n=566)   *p*-value[\*](#tfn1-cmar-10-2151){ref-type="table-fn"}                                  
  ------------------- -------- --------------------------------------- -------------------------------------------------------- --------------------------------------- -------------------------------------------------------- --------------------------------------- -------------------------------------------------------- --------------------------------------- -------------------------------------------------------- ------------------------------------------- -------------------------------------------------------- ---- ------------- ----- ----- -------------
  Gender              Male     141                                     209                                                      0.477                                   345                                                      81                                      0.144                                                    108                                     319                                                      0.092                                       398                                                      41   0.304         202   156   **0.001**
  Female              89       116                                                                                              217                                     37                                                                                               50                                                       205                                                                                              230                                         31                                                            86            122         
  Age (years)         ≤60      148                                     173                                                      \<**0.001**                             270                                                      39                                      **0.003**                                                59                                      250                                                      **0.023**                                   299                                                      14   \<**0.001**   150   107   **0.001**
  \>60                82       152                                                                                              292                                     79                                                                                               99                                                       274                                                                                              329                                         58                                                            138           171         
  Smoking             Yes      39                                      63                                                       0.505                                   90                                                       28                                      0.060                                                    30                                      88                                                       0.549                                       112                                                      8    0.187         62    41    **0.039**
  No                  191      262                                                                                              472                                     90                                                                                               128                                                      436                                                                                              516                                         64                                                            226           237         
  Drinking            Yes      25                                      34                                                       0.890                                   47                                                       15                                      0.158                                                    18                                      44                                                       0.269                                       60                                                       3    0.189         34    26    0.413
  No                  205      291                                                                                              515                                     103                                                                                              140                                                      480                                                                                              568                                         69                                                            254           252         
  Hypertension        Yes      41                                      60                                                       0.911                                   117                                                      20                                      0.379                                                    32                                      106                                                      1.000                                       123                                                      19   0.215         59    46    0.236
  No                  189      265                                                                                              445                                     98                                                                                               126                                                      418                                                                                              505                                         53                                                            229           232         
  Diabetes            Yes      19                                      15                                                       0.105                                   34                                                       12                                      0.109                                                    17                                      30                                                       **0.047**                                   41                                                       10   **0.031**     15    22    0.234
  No                  211      310                                                                                              528                                     106                                                                                              141                                                      494                                                                                              587                                         62                                                            273           256         
  Chemotherapy        Yes      152                                     214                                                      1.000                                   366                                                      87                                      0.085                                                    118                                     335                                                      **0.012**                                   421                                                      43   0.237         190   182   0.930
  No                  78       111                                                                                              196                                     31                                                                                               40                                                       189                                                                                              207                                         29                                                            98            96          
  Tumor grade         G1--G2   209                                     286                                                      0.332                                   500                                                      109                                     0.323                                                    141                                     470                                                      0.882                                       101                                                      66   0.687         254   250   0.591
  G3--G4              21       39                                                                                               62                                      9                                                                                                17                                                       54                                                                                               527                                         6                                                             34            28          
  Tumor stage         I        15                                      60                                                       \<**0.001**                             83                                                       7                                       **0.013**                                                10                                      80                                                       **0.007**                                   86                                                       5    0.232         54    21    \<**0.001**
  II                  102      142                                                                                              247                                     49                                                                                               68                                                       229                                                                                              272                                         36                                                            122           130         
  III                 113      123                                                                                              232                                     62                                                                                               80                                                       215                                                                                              270                                         31                                                            112           127         
  Depth of invasion   T1--T2   15                                      73                                                       \<**0.001**                             99                                                       7                                       **0.001**                                                10                                      96                                                       \<**0.001**                                 101                                                      6    0.086         63    25    \<**0.001**
  T3--T4              215      252                                                                                              463                                     111                                                                                              148                                                      428                                                                                              527                                         66                                                            225           253         
  Lymph node status   N0       117                                     202                                                      **0.009**                               330                                                      56                                      **0.032**                                                78                                      309                                                      \<**0.001**                                 358                                                      41   1.000         176   151   0.107
  N1--N2              113      123                                                                                              232                                     62                                                                                               80                                                       215                                                                                              270                                         31                                                            112           127         
  Tumor size (cm)     ≤5       111                                     251                                                      \<**0.001**                             391                                                      40                                      \<**0.001**                                              61                                      371                                                      \<**0.001**                                 411                                                      30   \<**0.001**   219   148   \<**0.001**
  \>5                 119      74                                                                                               171                                     78                                                                                               97                                                       153                                                                                              217                                         42                                                            69            130         
  CA199 (U/mL)        ≤37      174                                     270                                                      **0.006**                               443                                                      88                                      0.592                                                    120                                     411                                                      0.761                                       495                                                      43   \<**0.001**   243   207   **0.009**
  \>37                40       37                                                                                               73                                      18                                                                                               24                                                       68                                                                                               83                                          10                                                            28            50          
  NA                  16       18                                                                                               46                                      12                                                                                               14                                                       45                                                                                               50                                          19                                                            17            21          
  CEA (ng/mL)         ≤5       128                                     228                                                      **0.002**                               355                                                      62                                      **0.002**                                                87                                      330                                                      0.182                                       393                                                      31   \<**0.001**   206   155   \<**0.001**
  \>5                 86       81                                                                                               163                                     44                                                                                               57                                                       151                                                                                              187                                         22                                                            67            102         
  NA                  16       16                                                                                               44                                      12                                                                                               14                                                       43                                                                                               48                                          19                                                            15            21          
  OS                  Alive    176                                     290                                                      \<**0.001**                             477                                                      87                                      **0.005**                                                118                                     448                                                      **0.002**                                   526                                                      51   **0.009**     258   217   \<**0.001**
  Dead                54       35                                                                                               85                                      31                                                                                               40                                                       76                                                                                               102                                         21                                                            30            61          

**Notes:**

Difference between groups was tested by chi-square test. *p*-value \<0.05 shown in bold.

**Abbreviations:** AFR, albumin-to-fibrinogen ratio; Alb, albumin; CA199, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CRC, colorectal cancer; Fib, fibrinogen; FPR, fibrinogen-to-pre-albumin ratio; NA, not available; OS, overall survival.

###### 

Univariate and multivariate analyses of prognostic factors for 3-year overall survival by Cox regression model

  Variables                   Overall survival                                            
  --------------------------- ---------------------- ------------- ---------------------- -------------
  Sex (female)                0.880 (0.606--1.277)   0.501         --                     --
  Age (\>60 years)            1.223 (0.851--2.805)   0.277         --                     --
  Alcohol (yes)               1.186 (0.654--2.152)   0.575         --                     --
  Tobacco (yes)               0.995 (0.622--1.591)   0.982         --                     --
  Hypertension (yes)          0.878 (0.558--1.382)   0.575         --                     --
  Diabetes (yes)              1.115 (0.584--2.130)   0.741         --                     --
  Chemotherapy (yes)          0.882 (0.611--1.274)   0.504         --                     --
  Tumor grade (G3--G4)        1.867 (1.145--3.046)   **0.012**     1.718 (1.052--2.805)   **0.030**
  Tumor stage (III)           3.834 (1.567--9.381)   **0.003**     3.368 (1.370--8.280)   **0.008**
  Depth of invasion (T3-T4)   3.792 (1.669--8.614)   **0.001**     2.792 (1.208--6.452)   **0.016**
  lymph node (N1--N3)         1.934 (1.354--2.762)   \<**0.001**   1.888 (1.322--2.698)   \<**0.001**
  Tumor size (\>5 cm)         1.979 (1.389--2.819)   \<**0.001**   1.905 (1.336--2.715)   **0.001**
  CEA (\>5 ng/mL)             2.961 (2.019--4.342)   \<**0.001**   2.719 (1.850--3.996)   \<**0.001**
  CA199 (\>37 U/mL)           2.916 (1.934--4.398)   \<**0.001**   2.605 (1.683--4.033)   \<**0.001**
  Fib (\>3.8 mg/dL)           1.913 (1.304--2.806)   **0.001**     1.450 (0.961--2.188)   0.077
  Alb (\>33.3 g/L)            0.504 (0.315--0.806)   **0.004**     0.564 (0.349--0.912)   **0.020**
  pre-Alb (\>187.4 mg/L)      0.444 (0.287--0.687)   \<**0.001**   0.520 (0.329--0.823)   **0.005**
  AFR (\>9.2)                 0.531 (0.352--0.801)   **0.003**     0.709 (0.455--1.107)   0.130
  FPR (\>18.3)                2.398 (1.567--3.669)   \<**0.001**   1.940 (1.236--3.046)   **0.004**

**Notes:** Adjusted HR (95%) was adjusted by sex, age, alcohol, tobacco, hypertension, diabetes, chemotherapy, tumor size, tumor grade, and tumor stage. The endash represent that these variables were not included in the multivariate cox regression. *p*-value \<0.05 shown in bold.

**Abbreviations:** AFR, albumin/fibrinogen ratio; Alb, albumin; pre-Alb, pre-albumin; CA199, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; Fib, fibrinogen; FPR, fibrinogen-to-pre-albumin ratio; HR, hazard ratio.
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